Get the Stockscreener App
7.64
0.66%
0.05
Pre-market:
7.72
0.08
+1.05%
Moleculin Biotech Inc stock is traded at $7.64, with a volume of 115.86K.
It is up +0.66% in the last 24 hours and down -38.47% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$7.59
Open:
$7.53
24h Volume:
115.86K
Relative Volume:
0.84
Market Cap:
$15.81M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.4995
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+9.14%
1M Performance:
-38.47%
6M Performance:
-54.63%
1Y Performance:
-87.82%
1-Day Range:
$7.27
$7.75
1-Week Range:
$6.0101
$7.75
52-Week Range:
$6.0101
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
7.64 | 15.71M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ
How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser
Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Price to cash flow ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Why analysts maintain buy rating on Moleculin Biotech Inc. (MOL) stockGDP Growth & Reliable Momentum Entry Alerts - Newser
Number of employees of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Moleculin Biotech, Inc. Financial Statements – FWB:MOL0 - TradingView
Non-controlling/minority interest of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Diluted net income available to common stockholders of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Operating income of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Gross profit of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Statistics – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Cash Flow – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Balance Sheet – BER:MOL0 - TradingView
Moleculin Biotech: Dividend historical data and projections - MarketScreener
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018 - marketscreener.com
How forex fluctuations impact Moleculin Biotech Inc. (MOL) stockWeekly Trend Report & Accurate Intraday Trading Signals - Newser
MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - Bitget
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Moleculin Biotech files for stock and warrants offering - MSN
Moleculin Biotech To Present Corporate Overview At Virtual Investor Closing Bell Series - Nasdaq
Will Moleculin Biotech Inc. stock rally after Fed decisionsJuly 2025 Patterns & Low Drawdown Trading Techniques - moha.gov.vn
Moleculin Biotech Bets Big On New Cancer Drug Trials - Finimize
Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Review & Free High Return Stock Watch Alerts - BỘ NỘI VỤ
Why Moleculin Biotech Inc. stock is considered a top pick2025 Fundamental Recap & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Moleculin Biotech stock drops after announcing 1-for-25 reverse split - Investing.com
Moleculin Biotech announces 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Moleculin Biotech falls after reverse stock split move - TradingView
Moleculin to Participate in the Virtual Investor Closing Bell Series - The Manila Times
Moleculin Biotech announces 1-for-25 reverse stock split - Investing.com
Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative
Moleculin Announces Reverse Stock Split - marketscreener.com
Moleculin Biotech (Nasdaq: MBRX) Reverse Split to Cut Shares from 51.7M to 2.1M - Stock Titan
Moleculin Biotech Reports Increased Loss Amid Ongoing Trials - MSN
Moleculin Biotech Releases Corporate Presentation Update - TipRanks
Pre Market Movers: OSCR, NITO, CLSD Set The Pace - RTTNews
Moleculin Biotech receives Nasdaq delisting notice, plans to appeal By Investing.com - Investing.com Nigeria
Moleculin Biotech receives Nasdaq delisting notice, plans to appeal - Investing.com
Moleculin Biotech Appeals Nasdaq Delisting Decision - TipRanks
[8-K] Moleculin Biotech, Inc. Reports Material Event | MBRX SEC FilingForm 8-K - Stock Titan
Moleculin Biotech Releases New Corporate Presentation - MSN
Why analysts remain bullish on Moleculin Biotech Inc. stockDividend Hike & Daily Chart Pattern Signal Reports - newser.com
Is Moleculin Biotech Inc. (MOL) stock positioned for digital growth eraChart Signals & Stock Timing and Entry Methods - newser.com
Market reaction to Moleculin Biotech Inc.’s recent newsWeekly Trade Summary & Safe Entry Momentum Tips - newser.com
Published on: 2025-11-20 06:00:51 - newser.com
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):